Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Sung-Bae Kim"'
Autor:
Shaheenah Dawood, Maria Konstantionva, Rebecca Dent, Florencia Perazzo, Sung-Bae Kim, Cynthia Villarreal-Garza, Sandra Franco, Ming-Shen Dai, Sergio Simon
Publikováno v:
BMC Proceedings, Vol 15, Iss S10, Pp 1-17 (2021)
Abstract Purpose The therapeutic landscape of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (mBC) has evolved considerably with the introduction of newer targeted agents and thei
Externí odkaz:
https://doaj.org/article/0462d2991d9442d385c3dd5b25517b3a
Autor:
Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Jung Hye Kwon, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hwan Jung Yun
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background By investigating treatment patterns and outcomes in locally advanced head and neck squamous cell carcinoma (LA-HNSCC), we aimed at providing valuable insights into the optimal therapeutic strategy for physicians in real-world prac
Externí odkaz:
https://doaj.org/article/288ade2c85504d48ab704fc86dc4f56f
Autor:
Stephen K. L. Chia, Miguel Martin, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gunter von Minckwitz, Janine Mansi, Carlos H. Barrios, Michael Gnant, Zorica Tomašević, Neelima Denduluri, Robert Šeparović, Sung-Bae Kim, Erik Hugger Jakobsen, Vernon Harvey, Nicholas Robert, John Smith, Graydon Harker, Bo Zhang, Lisa D. Eli, Yining Ye, Alshad S. Lalani, Marc Buyse, Arlene Chan
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Abstract Background Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that inhibits PI3K/Akt and MAPK signaling pathways after HER2 receptor activation. The ExteNET study showed that neratinib significantly improved 5-year invasive disea
Externí odkaz:
https://doaj.org/article/cf5037433d854254a48613d85af66f77
Autor:
Kyung-min Lee, Keesoo Nam, Sunhwa Oh, Juyeon Lim, Young-Pil Kim, Jong Won Lee, Jong-Han Yu, Sei-Hyun Ahn, Sung-Bae Kim, Dong-Young Noh, Taehoon Lee, Incheol Shin
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-3 (2019)
After the publication of this work [1] errors were found in Figs. 1a and 5d.
Externí odkaz:
https://doaj.org/article/2086d4a595704e9c809bb11d964e8283
Autor:
Hee Kyung Ahn, Eun Joo Kang, Seong Hoon Shin, Sung-Bae Kim, Y. Lee, Keon Uk Park, Jung Hye Kwon, Kyoung Eun Lee, Keun Wook Lee, Hwan Jung Yun, Hye Ryun Kim, Min Kyoung Kim, Jin-Soo Kim, Jin-Hyuk Choi, Bhumsuk Keam
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
BMC Cancer
BMC Cancer
Background By investigating treatment patterns and outcomes in locally advanced head and neck squamous cell carcinoma (LA-HNSCC), we aimed at providing valuable insights into the optimal therapeutic strategy for physicians in real-world practice. Met
Autor:
Neelima Denduluri, Marc Buyse, Robert Šeparović, Bent Ejlertsen, Stephen Chia, Gunter von Minckwitz, Alshad S. Lalani, Michael Gnant, Frankie A. Holmes, John A. Smith, Vernon Harvey, Bo Zhang, Hiroji Iwata, Janine Mansi, Beverly Moy, Sung-Bae Kim, Nicholas J. Robert, Yining Ye, Carlos H. Barrios, Erik Jakobsen, Arlene Chan, Suzette Delaloge, Miguel Martin, Lisa D. Eli, Z Tomasevic, Graydon Harker
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Chia, S K L, Martin, M, Holmes, F A, Ejlertsen, B, Delaloge, S, Moy, B, Iwata, H, von Minckwitz, G, Mansi, J, Barrios, C H, Gnant, M, Tomašević, Z, Denduluri, N, Šeparović, R, Kim, S-B, Jakobsen, E H, Harvey, V, Robert, N, Smith, J, Harker, G, Zhang, B, Eli, L D, Ye, Y, Lalani, A S, Buyse, M & Chan, A 2019, ' PIK3CA alterations and benefit with neratinib : analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial ', Breast Cancer Research, vol. 21, 39 . https://doi.org/10.1186/s13058-019-1115-2
Breast Cancer Research : BCR
Chia, S K L, Martin, M, Holmes, F A, Ejlertsen, B, Delaloge, S, Moy, B, Iwata, H, von Minckwitz, G, Mansi, J, Barrios, C H, Gnant, M, Tomašević, Z, Denduluri, N, Šeparović, R, Kim, S-B, Jakobsen, E H, Harvey, V, Robert, N, Smith, J, Harker, G, Zhang, B, Eli, L D, Ye, Y, Lalani, A S, Buyse, M & Chan, A 2019, ' PIK3CA alterations and benefit with neratinib : analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial ', Breast Cancer Research, vol. 21, 39 . https://doi.org/10.1186/s13058-019-1115-2
Breast Cancer Research : BCR
Background: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that inhibits PI3K/Akt and MAPK signaling pathways after HER2 receptor activation. The ExteNET study showed that neratinib significantly improved 5-year invasive disease-free
Autor:
Dong Young Noh, Jong Won Lee, Tae Hoon Lee, Sung-Bae Kim, Juyeon Lim, Sei Hyun Ahn, Kyungmin Lee, Young-Pil Kim, Incheol Shin, KeeSoo Nam, Jong Han Yu, Sunhwa Oh
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-3 (2019)
After the publication of this work [1] errors were found in Figs. 1a and 5d.